Lb Pharmaceuticals (LBRX) Prepaid Assets (2024 - 2026)

Lb Pharmaceuticals' quarterly Prepaid Assets came in at $1.4 million in Q1 2026, down 89.55% quarter-over-quarter from $13.2 million in Q4 2025.

Lb Pharmaceuticals has reported Prepaid Assets for 3 years, with the latest figure at $1.4 million in Q1 2026.

  • For the quarter ending Q1 2026, Prepaid Assets changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (changed N/A YoY), and the FY2025 full-year result was $13.2 million, up 4814.13% from the prior year.
  • Prepaid Assets for Q1 2026 stood at $1.4 million, down from $13.2 million in the prior quarter.
  • The five-year high for Prepaid Assets was $13.2 million in Q4 2025, with the low at $269000.0 in Q4 2024.
  • Average Prepaid Assets over 3 years is $4.2 million, with a median of $1.7 million recorded in 2025.
  • Peak annual rise in Prepaid Assets reached 4814.13% in 2025, while the deepest fall reached 4814.13% in 2025.
  • Tracing LBRX's Prepaid Assets over 3 years: stood at $269000.0 in 2024, then soared by 4814.13% to $13.2 million in 2025, then slumped by 89.55% to $1.4 million in 2026.
  • The last three Prepaid Assets figures came in at $1.4 million (Q1 2026), $13.2 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Lb Pharmaceuticals 789.92 Mn 789.92 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.38 Mn
Dec 31, 2025 13.22 Mn
Sep 30, 2025 1.92 Mn
Dec 31, 2024 269,000.00